Trials / Completed
CompletedNCT01024920
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIBF 1120 | VEGF inhibitor |
| DRUG | sunitinib | VEGF inhibitor |
Timeline
- Start date
- 2009-12-16
- Primary completion
- 2011-11-08
- Completion
- 2020-06-19
- First posted
- 2009-12-03
- Last updated
- 2021-07-19
- Results posted
- 2020-06-17
Locations
15 sites across 5 countries: Hungary, Poland, Romania, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01024920. Inclusion in this directory is not an endorsement.